Skip to main content

Table 1 Characteristics of the study patients (n = 164)

From: Clinical and immune profiling for cancer of unknown primary site

Characteristic No. of patients (%)a P valueb
Full-analysis set (n = 164) Biomarker-analysis set (n = 92)
Median age (range), years 68 (35–95) 68 (35–95) 0.915
Sex 0.427
 Male 94 (57) 58 (63)  
 Female 70 (43) 34 (37)  
ECOG performance status 0.909
 0–1 100 (61) 57 (62)  
 2 34 (21) 17 (18)  
 3–4 15 (9) 9 (10)  
 Unknown (not recorded) 15 (9) 9 (10)  
Smoking historyc 0.772
 Current or former 93 (57) 57 (62)  
 Never 49 (30) 27 (29)  
 Unknown (not recorded) 22 (13) 8 (9)  
Favorable subset 34 (21) 20 (22) 0.874
 Neuroendocrine carcinoma (NEC) 9 (5) 4 (4)  
 Squamous carcinoma limited to cervical lymph nodes (HNC-like) 13 (8) 10 (11)  
 Adenocarcinoma restricted to axillary lymph nodes in females (BC-like) 1 (1) 1 (1)  
 Extragonadal germ cell tumor syndrome (GCT-like) 1 (1) 1 (1)  
 Peritoneal carcinomatosis in females (PPC-like) 7 (4) 2 (2)  
 Squamous carcinoma limited to inguinal lymph nodes (ACC-like) 1 (1)   
 Single resectable metastatic carcinoma 2 (1) 2 (2)  
 Unfavorable subset 130 (79)d 72 (78)d  
Histology 0.759
 Squamous 33 (20) 21 (23)  
 Adeno 76 (46) 42 (46)  
 Undifferentiated 36 (22) 22 (24)  
 Other 19 (12)e 7 (8)f  
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group
  2. aPercentages may not add up to 100 because of rounding
  3. bFisher’s exact test
  4. cCurrent smokers were defined as individuals who had smoked ≥100 cigarettes including at least one within the year prior to diagnosis; former smokers as those who had smoked ≥100 cigarettes but had quit > 1 year prior to diagnosis; and never-smokers as those who had smoked < 100 cigarettes
  5. dA plausible primary site of origin was identified in one patient (primary differentiated thyroid carcinoma identified after second-line chemotherapy in a patient with multiple bone metastases)
  6. eAdenosquamous, n = 3; neuroendocrine carcinoma, n = 9; not otherwise specified, n = 7
  7. fAdenosquamous, n = 1; neuroendocrine carcinoma, n = 4; not otherwise specified, n = 2